Fate Therapeutics, Inc. (FRA:F6T)

Market Cap	142.95M -7.9%
Revenue (ttm)	6.08M -46.9%
Net Income	-133.04M
EPS	-1.12
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	205
Open	1.159
Previous Close	1.127
Day's Range	1.159 - 1.159
52-Week Range	0.600 - 1.619
Beta	n/a
RSI	63.24
Earnings Date	Feb 26, 2026

About Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 181
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: F6T

Financial Performance

In 2024, Fate Therapeutics's revenue was $13.63 million, a decrease of -78.55% compared to the previous year's $63.53 million. Losses were -$186.26 million, 15.7% more than in 2023.

Financial numbers in USD